ReviewCurrent issues in molecular biology2023
Multiple Sclerosis: Inflammatory and Neuroglial Aspects.
Review in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Heart rate variability in people with multiple sclerosis: A systematic review and meta-analysis.Acta neurologica Belgica · 2026Pooled it
- The Association Between Serum α-Tocopherol and Pathogenesis of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Case-Control Studies.BioMed research international · 2026Pooled it
- Quantitative Susceptibility Mapping Values Quantification in Deep Gray Matter Structures for Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.Brain and behavior · 2024Pooled it
- Effect of Metabolic and Bariatric Surgery on the Clinical Course of Multiple Sclerosis in Patients with Severe Obesity: a Systematic Review.Obesity surgery · 2023Pooled it
- Serum amylin levels in patients with multiple sclerosis: A cross-sectional case-control study.Medicine · 2026Article
- Common Inflammatory Pathways Between Periodontal Disease and Multiple Sclerosis: A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
- Phosphorylated Neurofilament Heavy Chain in Cerebrospinal Fluid and Serum as a Biomarker of Axonal Injury in Algerian Patients with Multiple Sclerosis.Diseases (Basel, Switzerland) · 2026Article
- Natural Killer Cells: Dual Regulators and Therapeutic Targets in Multiple Sclerosis Immunopathogenesis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Low-intensity transcranial ultrasound neuromodulation promotes neuronal regeneration: A new hope for noninvasive treatment of neurodegenerative diseases.Neural regeneration research · 2026Article
- FreeSurfer-Based MRI Volumetry Reveals Thalamic and Hippocampal Atrophy as Significant Correlates of Disability in Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2026Article
- Structural Characterization, Toxicity Assessment and Molecular Modeling of Forced Degradation Products of Siponimod.International journal of molecular sciences · 2026Article
- Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.Advances in therapy · 2026Article
- Trained Immunity in Autoimmunity: Friend, Foe, or Therapeutic Target?Biomedicines · 2026Article
- Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.Acta neuropsychiatrica · 2026Review
- Exosomes as mediators of repair and immunoregulation in multiple sclerosis: a new frontier in cell-free therapy.Molecular biology reports · 2026Review
- Risk factors affecting the age at onset in adult patients with multiple sclerosis.BMC neurology · 2026Article
- Non-invasive visual theta entrainment modulates myelin-related and functional outcomes in an LPC-induced demyelination model.PloS one · 2026Article
- A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.Frontiers in immunology · 2026Article
- Trends in Nanoparticle-based Strategies for the Management of Neuroinflammation.CNS & neurological disorders drug targets · 2026Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) represents the most common acquired demyelinating disorder of the central nervous system (CNS). Its pathogenesis, in parallel with the well-established role of mechanisms pertaining to autoimmunity, involves several key functions of immune, glial and nerve cells. The disease's natural history is complex, heterogeneous and may evolve over a relapsing-remitting (RRMS) or progressive (PPMS/SPMS) course. Acute inflammation, driven by infiltration of peripheral cells in the CNS, is thought to be the most relevant process during the earliest phases and in RRMS, while disruption in glial and neural cells of pathways pertaining to energy metabolism, survival cascades, synaptic and ionic homeostasis are thought to be mostly relevant in long-standing disease, such as in progressive forms. In this complex scenario, many mechanisms originally thought to be distinctive of neurodegenerative disorders are being increasingly recognized as crucial from the beginning of the disease. The present review aims at highlighting mechanisms in common between MS, autoimmune diseases and biology of neurodegenerative disorders. In fact, there is an unmet need to explore new targets that might be involved as master regulators of autoimmunity, inflammation and survival of nerve cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.